• Galderma will present findings from the ARTIST post-marketing study showing that The Shayping Technique™ – a holistic treatment approach using three Restylane^® injectables – significantly enhances facial features and overall appearance, supporting its use to meet diverse patient needs¹
• Additional presentations will highlight the versat

• Both trials met their primary endpoints, demonstrating treatment with RelabotulinumtoxinA resulted in a statistically significant improvement in frown lines and crow’s feet.^1,2
• Results reinforce the rapid onset of action of RelabotulinumtoxinA, with some patients reporting improvement as early as day one in both trials.^1,2

Galderma is the only pure-play dermatology company with more than 40 years of heritage, and its significant presence at the 25th World Congress of Dermatology (WCD) underscores its leadership in this space. More details on Galderma’s scientific presentations at WCD can be found below.

Galderma will unveil updates from its dermatology portfolio at the 34^th European Academy of Dermatology and Venereology (EADV) congress, taking place in Paris on September 17-20, 2025, including data on prurigo nodularis, atopic dermatitis, and sensitive skin. 

• New label update allows for immediate use after reconstitution and more convenient administration of SCULPTRA^® with the optional addition of lidocaine for increased patient comfort